Zentek Ltd. (ZEN.V)
| Previous Close | 1.5500 |
| Open | 1.5500 |
| Bid | 1.5200 x 0 |
| Ask | 1.5800 x 0 |
| Day's Range | 1.5300 - 1.5900 |
| 52 Week Range | 1.3000 - 2.3000 |
| Volume | |
| Avg. Volume | 36,817 |
| Market Cap | 160.304M |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREZentek Announces U.S. Distribution Agreement for ZenGUARDTM-Enhanced Surgical Masks with Medwell Solutions
GUELPH, ON / ACCESSWIRE / April 3, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, is pleased to announce that it has entered into a definitive distribution ...
- ACCESSWIRE
Zentek Announces Promising Preclinical Safety and Toxicity Results achieved by Triera Biosciences Ltd. for C19HBA
GUELPH, ON / ACCESSWIRE / March 25, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera") has completed testing demonstrating that its C19HBA SARS-CoV-2 ...
- ACCESSWIRE
Zentek Announces Positive Therapeutic Results achieved by Triera Biosciences for C19HBA
GUELPH, ON / ACCESSWIRE / January 30, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN) announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera")has completed testing of its C19HBA aptamer as a potential therapeutic. ...
